WO2024047241A1 - Traitement de la fasciolose - Google Patents

Traitement de la fasciolose Download PDF

Info

Publication number
WO2024047241A1
WO2024047241A1 PCT/EP2023/074068 EP2023074068W WO2024047241A1 WO 2024047241 A1 WO2024047241 A1 WO 2024047241A1 EP 2023074068 W EP2023074068 W EP 2023074068W WO 2024047241 A1 WO2024047241 A1 WO 2024047241A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
fasciolosis
use according
mammal
compounds
Prior art date
Application number
PCT/EP2023/074068
Other languages
English (en)
Inventor
Michael Berger
Ulrich Sondern
Original Assignee
Intervet International B.V.
Intervet Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International B.V., Intervet Inc. filed Critical Intervet International B.V.
Publication of WO2024047241A1 publication Critical patent/WO2024047241A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Definitions

  • the present invention relates to compounds and compositions for treating fasciolosis in a mammal.
  • Fasciolosis is an important zoonotic disease that is responsible for a significant loss in food resource and animal productivity. Fasciolosis is a disease of both veterinary and public health importance, infecting over 600 million animals. The infection causes massive loss through liver condemnation, reduced production of milk, meat, and wool, veterinary care, metabolic disease as well as mortality
  • Fasciolosis is caused by the trematode parasite Fasciola spp. Fasciola hepatica and Fasciola gigantica are the two main species responsible for most fasciolosis cases in mammals. Fasciola hepatica is cosmopolitan in nature because of its ability to infect a variety of species, while Fasciola gigantica is more common in tropical countries, though both species are found in Africa and Asia.
  • Fasciolosis can result from the migration of large numbers of immature fluke larvae through the liver, from the presence of adult flukes in the bile ducts, or both. Fasciolosis occurs in three main clinical forms - acute, subacute and chronic fasciolosis. Which form occurs depends on the numbers of infective metacercariae ingested and the period over which they are ingested.
  • fasciolosis The primary impact of fasciolosis is on farmed ruminants, however, they are not selective regarding the final host and successfully infect a wide range of mammals, including humans. Among the farmed ruminants, fasciolosis may cause annual economic losses of several billions of dollars world-wide.
  • Mature F. hepatica are large, leaf-shaped trematodes; about 3 to 5 cm in length and 1 cm in width. Both the immature and the mature stages of the parasite feed by secreting enzymes, most notably cysteine proteases, which break down blood and the liver tissue. The parasites irritate the walls of the bile ducts causing hyperplasia of the bile duct epithelium.
  • triclabendazole (TCBZ)
  • TABZ triclabendazole
  • immature stages i.e. early immature larvae (1 to 6 weeks old) and immature larvae (6 to 9 weeks old).
  • it is the only flukicide effective against all early immature liver fluke larvae.
  • Isoxazoline compounds are known in the art and these compounds are described, for example, in US patent application US 2007/0066617, and international patent applications WO 2005/085216, WO 2007/079162, WO 2009/002809, WO 2009/024541, WO 2009/003075, WO 2009/080250, WO 2010/070068 and WO 2010/079077.
  • This class of compounds is known to possess excellent activity against ectoparasites i.e. parasites that have their permanent or temporary habitat on the external surface of animals, such as parasitic insects and acarids such as ticks and fleas and mites.
  • ectoparasites i.e. parasites that have their permanent or temporary habitat on the external surface of animals, such as parasitic insects and acarids such as ticks and fleas and mites.
  • the Applicant has addressed the problems of the prior art by identifying compounds that are effective at treating fasciolosis.
  • the current invention provides a compound of Formula (I)
  • R 1 - R 5 is H, F, Cl or CF 3
  • X is O or S, preferably O
  • Y is selected from
  • - denotes the bond to the carbonyl group for use in the treatment of fasciolosis of mammals.
  • Another aspect of the current invention is a composition comprising such compound and a pharmaceutically acceptable carrier for use in the treatment of fasciolosis of mammals.
  • the compound for use according to the current invention is tigolaner.
  • Fasciolosis refers to a clinical or subclinical disease of mammals in connection with an infection of a mammal with Fasciola hepatica or Fasciola gigantica.
  • the fasciolosis is due to liver fluke infestation by immature or early immature stage and symptoms caused by such infestation.
  • Fascioliosis ranges in severity from a devastating disease in sheep, and pseudo-ruminants such as alpacas, and llamas to a subclinical infection that is more common in cattle.
  • Acute disease occurs 2-6 weeks after the ingestion of large numbers of metacercaria over a short period.
  • acute fascioliosis occurs seasonally and is manifest by a distended, painful abdomen; anemia; and sudden death.
  • the acute syndrome can be complicated by concurrent infections with Clostridium novyi, resulting in black disease (clostridial necrotic hepatitis).
  • subacute disease In subacute disease, large numbers of metacercaria are ingested over longer periods of time; survival is longer (7-10 weeks), even in cases with extensive hepatic damage, but deaths occur because of hemorrhage and anemia.
  • Subacute fasciolosis is characterized by jaundice, some ill thrift and anemia. The burrowing fluke stages causes extensive tissue damage, leading to hemorrhaging and liver damage. The outcome is severe anemia, liver failure and death.
  • Chronic fascioliosis can occur in any season, but it manifests primarily in late fall and winter. It occurs as a result of ingesting moderate numbers of metacercariae over much longer periods of time.
  • Chronic fasciolosis is the most common form of liver fluke infection in sheep, goats and cattle - and particularly in more resistant hosts, such as horses and pigs. It occurs when the parasites reach the bile ducts in the liver. The fluke ingests blood, which produces severe anemia and chronic inflammation and enlargement of the bile ducts. The clinical signs develop slowly. The animals become increasingly anemic, appetite is lowered, the mucous membranes of the mouth and eyes become pale, and some animals develop oedema under the jaw ('bottle jaw'). Affected animals are reluctant to travel.
  • Significant production losses caused by (especially subcl inical) fasciolosis in livestock include reduced production and quality of wool, reduced lambing percentages, poor growth rate of lambs and/or increased costs for replacement stock in sheep; reduced calving percentages, poor growth rate of calves and/or increased costs for replacement stock in cattle; reduced production and quality of milk in dairy cattle and lower growth rates and lower feed conversion rates in fattening cattle.
  • live fluke infection refers to infestation of a mammal with Fasciola hepatica or Fasciola gigantica parasites. Unless otherwise indicated the term includes infestation or infection by flukes at any stage of maturity and mixtures of stages of maturity.
  • Fasciola spp. can be categorized into three stages, early immature, immature, and mature (commonly termed the adult stage).
  • the fasciolosis is due to liver fluke infection by early immature stage liver fluke i.e., by early immature larvae (1 to 6 weeks old).
  • the fasciolosis is due to liver fluke infection by immature stage liver fluke i.e., by immature larvae (6 to 9 weeks old).
  • the fasciolosis is due to liver fluke infection by mature stage liver fluke i.e., by mature flukes (>9 weeks old).
  • the compound for use according to the invention is effective against all immature liver fluke larvae.
  • the compound for use according to the invention is effective against all stages of liver flukes.
  • mammal refers to warm-blooded vertebrate animals having hair or fur and secrete milk by the females for the nourishment of the young and includes humans.
  • mammals are ruminants, for example cattle, sheep, goats, bison, African buffalo, water buffalo, antelopes, deer, moose, elks, and giraffes.
  • pseudo-ruminants for example, llamas and alpacas.
  • mammal included in the term mammal are other susceptible animals such as horses, pigs and donkeys.
  • mammals are understood to be sheep, goats, bison, African buffalo, water buffalo, and cattle. Even more particularly, mammals are sheep and cattle.
  • the mammal is a ruminant.
  • the mammal is selected from the group consisting of sheep and cattle.
  • the ruminant is sheep.
  • the ruminant is cattle.
  • veterinary has the same definition as “pharmaceutical” but adapted to mammal animals (meaning non-human beings).
  • a "veterinary drug” means a compound or mixture of compounds (conventionally together with inert formulation ingredients) , which is used, or is manufactured, sold or represented as suitable for use, in the diagnosis, treatment, control, eradication, mitigation or prevention of disease or abnormal physical or mental state or the symptoms thereof in an animal; or restoring, correcting, controlling, or modifying any physical, mental or organic function in an animal.
  • 'treatment' refers to the administration of an effective amount of the compound as described for use in the invention to a mammal which has been diagnosed with and /or shows symptoms of fasciolosis of more or less severity.
  • the skilled clinician can readily determine a mammal in need of the present treatment.
  • the typical symptoms of acute, subactute and chronic fascilosis have been described earlier.
  • the fasciolosis as cause of the symptoms can be detected by antibody testing, specifically ELISA testing, in particular of the blood and milk.
  • the fasciolosis as cause of the symptoms by detection of the Fasciola spp. infection can also be diagnosed by examining fecal specimens, including by ELISA testing. Moreover, modeling based on season, rainfall, temperature, and other local conditions can be used to predict times when fasciolosis is more likely.
  • fasciolosis is treated during autumn, winter, or early spring season.
  • liver fluke stages present at this high-risk period.
  • the compounds for use according to the invention are especially useful - in a situation wherein fasciolosis of the mammal- especially cattle or sheep- is due to an immature stage liver fluke infection and such infection is treated during autumn, winter, or early spring season.
  • fasciolosis of the mammal- especially cattle or sheep- is due to an immature stage liver fluke infection and such infection is treated during autumn, winter, or early spring season.
  • This provides a very useful treatment option to treat fasciolosis and the symptoms of such disease during the season with especially high risk of damage to the infected animal. During such season the immature stages of liver fluke are predominantly.
  • the compound for use according to the current invention is used for treatment during summer, sometimes called mid-season treatment in which predominantly adult stages of liver flukes and symptoms caused by this infection are present in the treated mammal. In Australia this is done during the months January/ February.
  • an "effective amount” for use in the invention is the amount, therapeutic dose, or quantity of a compound as described herein, that is required for a significant reduction of the parasites infesting such animal and when administered to a mammal for treating a disease, is sufficient to ameliorate or prevent the symptoms of acute, subacute or chronical fasciolosis to effect such treatment for the disease.
  • the "therapeutically effective amount" for the treatment of the different forms of fasciolosis will vary depending on the specific compound, the veterinary drug form, the age, weight, etc., of the mammal to be treated.
  • Compounds of Formula (I) for use in the current invention are:
  • X is O or S, preferably O
  • Y is selected from wherein denotes the bond to the isoxazoline or isothiazoline
  • the compound is 4-[5- (3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-/ ⁇ /-[(2,2,2-trifluoro- ethylcarbamoyl)-methyl]-benzamide (CAS RN 864731-61-3). This compound is also known as fluralaner.
  • the compound is 4-[5- [3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2- trifluoroethyl)amino]ethyl]-l-naphthalene-carboxamide (CAS RN 1093861-60-9).
  • This compound is also known as a 4-[5-(5-chloro-a,a,a-trifluoro-m-tolyl)-4,5-dihydro-5-(trifluoromethyl)-l,2-oxazol- 3yl]-/V-[2-oxo-2-[(2,2,2-trifluoroethylamino]ethyl]naphthalene-l-or afoxolaner.
  • Afoxolaner is for example disclosed in WO 2007/079162.
  • the isoxazoline compound is Esafoxolaner.
  • the compound is l-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H- spiro[azetidine-3,l'-isobenzofuran]-l-yl)-2-(methylsulfonyl)ethan-l-one, preferably l-(5'-((5S)-(5- (3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azetidine-3, - isobenzofuran]-l-yl)-2-(methylsulfonyl)ethan-l-one (CAS RN: 1398609-39-6). This compound is known as sarolaner.
  • the compound is 3- methyl-N-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-5-[5-(3,4,5-trichlorophenyl)-5- (trifluoromethyl)-4,5-dihydroisoxazol-3-yl]thiophene-2-carboxamide, preferably methyl-N-(2-oxo-2- ((2,2,2-trifluoroethyl)amino)ethyl)-5-[(5S)-5(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5- dihydroisoxazol-3-yl]thiophene-2-carboxamide (CAS RN: 1369852-71-0). This compound is known as lotilaner.
  • a compound used as alternative is 2-chloro-/V-(l-cyanocyclopropyl)-5-[l-[2-methyl-5-(l,l,2,2,2-pentafluoroethyl)-4- (trifluoromethyl)pyrazol-3-yl]pyrazol-4-yl]benzamide (CAS RN 1621436) This compound is known as tigolaner.
  • the compound is 4H- Cyclopenta[c]thiophene-l-carboxamide, 3-[(5S)-5-(3,5-dichloro-4- fluorophenyl)-4,5-dihydro-5- (trifluoromethyl)-3-isoxazolyl]-N-[2-[(2,2- difluoroethyl)amino]-2-oxoethyl]-5,6-dihydro- (CAS 1414642-93-5). This compound is known as mivorilaner.
  • the compound of Formula (I) is (Z)-4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-N-[(methoxy- imino)methyl]-2-methylbenzamide (CAS RN 928789-76-8).
  • the compound is 4-[5- (3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(thietan-3-yl) benzamide (CAS RN 1164267-94-0) that was disclosed in WO 2009/0080250.
  • the compound is 5-[5- (3,5-dDichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2- trifluoroethyl) amino] ethyl]- 2-thiophenecarboxamide (CAS RN 1231754-09-8) that was disclosed in WO 2010/070068.
  • the compound of Formula (I) is selected from fluralaner (including (S) fluralaner), afoxolaner (including esafoxolaner), sarolaner, or lotilaner.
  • fluralaner corresponding to 4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5- dihydroisoxazol-3-yl]-2-methyl-/ ⁇ /-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide
  • systemic insecticide and/or acaricide a) which is represented by Formula (II)
  • the compounds for use according to the current invention may exist in various isomeric forms.
  • a reference to a compound always includes all possible isomeric forms of such a compound.
  • a compound structure that does not indicate a particular conformation is intended to encompass compositions of all the possible conformational isomers of the compound, as well as compositions comprising fewer than all the possible conformational isomers.
  • Compounds of Formula (I) can be prepared according to one or other of the processes described e.g., in patent applications US 2007/0066617, WO 2007/079162, WO 2009/002809, WO 2009/080250, WO 2010/070068, WO 2010/079077, WO 2011/075591 and WO 2011/124998 or any other process coming within the competence of a person skilled in the art who is an expert in chemical synthesis.
  • composition for use according to the invention comprising more than one pharmaceutically active ingredient, i.e. wherein the composition for oral administration comprises another active pharmaceutical ingredient.
  • the term “comprise,” or variations thereof such as “comprises” or “comprising,” are to be read to indicate the inclusion of any recited integer (e.g., a feature, element, characteristic, property, method/process step or limitation) or group of integers (e.g., features, element, characteristics, properties, method/process steps or limitations) but not the exclusion of any other integer or group of integers.
  • combination with as well as “combination” and “synergistic combination” as used herein are taken to mean that a compound different from a compound of Formula (I) or another compound of Formula (I) is administered prior to, during, or after the administration of an compound of Formula (I). That is, in these are administered either sequentially or simultaneously to the mammal.
  • the combination is with a compound different from a compound of Formula (I).
  • sequentially administration means administration of within three days of administration of the other.
  • the compounds for use of the current invention are administered together with the combination compound within a day of each other and even more typically on the same day.
  • Sequential administration also means administration of such compounds within an hour, or even minutes, of administration of the othe compound.
  • Simultaneous administration includes preferably the presence of such compounds in the same veterinary product.
  • active ingredients which may include, without limitation antiparasitics such as endoparasiticides (including anthelmintics) and ecto-parasiticides, hormones and/or derivatives thereof, anti-inflammatory compounds and minerals and vitamins.
  • antiparasitics such as endoparasiticides (including anthelmintics) and ecto-parasiticides, hormones and/or derivatives thereof, anti-inflammatory compounds and minerals and vitamins.
  • a combination with selenium especially as sodium selenate.
  • the active ingredients are preferably antiparasitics, more preferably endoparasiticides, preferably anthelmintics and are preferably selected from the group consisting of avermectins (e.g., ivermectin, doramectin, abamectin, eprinomectin); milbemycins (moxidectin and milbemycin oxime); probenzimidazoles (e.g., febantel, netobimin, and thiophanate); benzimidazole derivatives, such as a thiazole benzimidazole derivatives (e.g., thiabendazole and cambendazole), carbamate benzimidazole derivatives (e.g., fenbendazole, albendazole (oxide), mebendazole, oxfendazole, parbendazole, oxibendazole, flubendazole, and triclabendazole); imidazothi
  • ivermectin eprinomectin
  • moxidectin levamisole
  • fenbendazole abamectin, monepantel, derquantel, oxfendazole, albendazole, closantel and combinations thereof.
  • An effective amount of the compound for use according to the current invention is administered to the mammal orally or parenterally.
  • an effective amount is administered orally to the mammal.
  • an effective amount is administered parenterally to the mammal.
  • the compounds are administered to an animal in need thereof in the form of a pharmaceutical or veterinary composition.
  • compositions for oral administration include components conventionally used in the art of formulation and may therefore be processed in a known manner to give, for example, solutions, emulsions, soluble powders, powder mixtures, granules or microencapsulation in polymeric substances.
  • Such formulations, preparations or compositions optionally include a solid or liquid adjuvant, and are produced in a manner well-known in the art, for example by intimately mixing and/or grinding the active ingredients with the adjuvants, for example with solvents, solid carriers, etc.
  • Oral administration can also be accomplished by drench, gavage, tablet, capsule, or in feed.
  • compositions are known to be suitable for oral administration to animals, but they vary for the different animal species.
  • Oral administration can be accomplished by conventional dosage forms, such as e.g. drench, gavage, tablet, capsule, or in feed.
  • Drenching means that a liquid, potentially slightly viscous pharmaceutical composition comprising the active pharmaceutical ingredient and excipients is applied via the mouth with a specific drenching gun that dispenses the composition into the sheep's throat.
  • Oral drench compositions are in general solutions or suspensions and generally not more than 20 ml, preferably not more than 15 ml of such drench are applied per sheep.
  • a concentrated solution is used to administer the compound for use according to the invention via drench application to sheep.
  • a suspension formulation is used for the drench application.
  • Excipients may comprise conventional non active pharmaceutically and veterinarily acceptable components or excipients e.g. fillers, binders, flavoring agents, solvents, colorants, glidants, preservatives, viscosity enhancer, surfactants, stabilizers, such as antioxidants.
  • excipients e.g. fillers, binders, flavoring agents, solvents, colorants, glidants, preservatives, viscosity enhancer, surfactants, stabilizers, such as antioxidants.
  • the pharmaceutical excipients are excipients with which the person skilled in the art is familiar, such as those which are described in the European Pharmacopoeia.
  • Parenteral administration includes injectable administration, especially subcutaneous administration. This is a preferred administration route for larger ruminant animals such as cattle.
  • compositions are known to be suitable for subcutaneous injection administration to animals, generally liquid compositions such as solutions or suspensions of the compounds of Formula (I) using pharmaceutically acceptable solvents and/or suspending agents.
  • the composition for subcutaneous administration can be either a liquid solution or suspension or a semi-solid or solid composition e.g., an implant.
  • a solution is a mixture of two or more components that form a single phase that is homogeneous down to the molecular level.
  • a suspension consists of insoluble solid particles dispersed in a liquid medium, with the solid particles accounting for about 0.5% to about 30% of the suspension.
  • the liquid may be aqueous, oily, or both.
  • a suitable injectable solution of compounds is a pharmaceutical composition that comprises an isoxazoline compound, and a pharmaceutically acceptable carrier comprising 2 pyrrolidone, PEG and propylene glycol.
  • a pharmaceutically acceptable carrier comprising 2 pyrrolidone, PEG and propylene glycol.
  • An alternative is an aqueous suspension.
  • the amounts of each of the components in the final product may be varied considerably, depending upon the nature of the pharmaceutically active ingredients, the weight and condition of the subject treated, and the unit dosage desired.
  • the effective dose of the compound of formula (I) is between 0.5 mg/kg bodyweight and 50 mg/kg bodyweight.
  • Those of ordinary skill in the art will be able to adjust dosage amounts for particular compounds in the composition in light of the teachings of this disclosure and the available information about such compounds.
  • the product according to the current invention conventionally further comprises physiologically acceptable formulation excipients known in the art e.g., as described in "Gennaro, Remington: The Science and Practice of Pharmacy” (20th Edition, 2000) incorporated by reference herein.
  • ingredients, carriers and excipients must be substantially pharmaceutically or veterinary pure and non-toxic in the amounts employed and must be compatible with the pharmaceutically active ingredients.
  • the veterinary composition for use according to the invention can be in one embodiment mixed with an existing commercial product before administration to an animal.
  • the composition includes a combination of an effective amount of a compound for use according to the current invention and another compound (or a commercial product with such compound) that controls a different parasite infestation, e.g., against parasitic helminths or alternatively ectoparasites, especially fly strike.
  • a different parasite infestation e.g., against parasitic helminths or alternatively ectoparasites, especially fly strike.
  • two compounds of Formula (I) as described above are included in a composition that control different parasites.
  • the viability detection of Fasciola hepatica NEJs is based on qualitative microscopic evaluation of motility and phenotype and additionally measuring propidium iodide to make use of the differential uptake of fluorophores (such as propidium iodide) by living organisms.
  • NEJs were prepared according to Edwards et al. [1], Approximately 12 NEJs/compound were cultivated. NEJ/compound co-cultures were placed at 37°C in a humidified atmosphere containing 5% CO2. NEJ/compound co-cultures were incubated for a total of 72 hrs. At 24h, an assessment of the gross phenotype was made for all NEJ/compound co-cultures and bright field images were captured. At 72h both phenotype and motility were quantified in comparison to live DMSO controls based on a microscopic scoring method detailed in [1] as well as summarised in Table 1 below.
  • PI Propidium Iodide

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés et des compositions de formule (I) pour le traitement d'une fasciolose chez un mammifère.
PCT/EP2023/074068 2022-09-02 2023-09-01 Traitement de la fasciolose WO2024047241A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22193586.9 2022-09-02
EP22193586 2022-09-02

Publications (1)

Publication Number Publication Date
WO2024047241A1 true WO2024047241A1 (fr) 2024-03-07

Family

ID=83191797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/074068 WO2024047241A1 (fr) 2022-09-02 2023-09-01 Traitement de la fasciolose

Country Status (1)

Country Link
WO (1) WO2024047241A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085216A1 (fr) 2004-03-05 2005-09-15 Nissan Chemical Industries, Ltd. Composé benzamide substitué par de l’isoxazoline et agent de contrôle d’organisme nocif
WO2007079162A1 (fr) 2005-12-30 2007-07-12 E. I. Du Pont De Nemours And Company Isoxazolines servant à lutter contre des animaux nuisibles invertébrés
WO2009002809A2 (fr) 2007-06-26 2008-12-31 E. I. Du Pont De Nemours And Company Agents de lutte contre les parasites invertebres
WO2009080250A2 (fr) 2007-12-24 2009-07-02 Syngenta Participations Ag Composés insecticides
WO2010070068A2 (fr) 2008-12-19 2010-06-24 Novartis Ag Composés organiques
WO2010079077A1 (fr) 2008-12-18 2010-07-15 Novartis Ag Dérivés isoxazolines et leur utilisation en tant que pesticide
WO2011075591A1 (fr) 2009-12-17 2011-06-23 Merial Limited Dihydroazoles antiparasitaires et compositions les incluant
WO2011124998A1 (fr) 2010-04-08 2011-10-13 Pfizer Inc. Dérivés de 3,5-diphényl-isoxazoline substitués comme insecticides et acaricides

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085216A1 (fr) 2004-03-05 2005-09-15 Nissan Chemical Industries, Ltd. Composé benzamide substitué par de l’isoxazoline et agent de contrôle d’organisme nocif
US20070066617A1 (en) 2004-03-05 2007-03-22 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and pesticide
WO2007079162A1 (fr) 2005-12-30 2007-07-12 E. I. Du Pont De Nemours And Company Isoxazolines servant à lutter contre des animaux nuisibles invertébrés
WO2009002809A2 (fr) 2007-06-26 2008-12-31 E. I. Du Pont De Nemours And Company Agents de lutte contre les parasites invertebres
WO2009080250A2 (fr) 2007-12-24 2009-07-02 Syngenta Participations Ag Composés insecticides
WO2010079077A1 (fr) 2008-12-18 2010-07-15 Novartis Ag Dérivés isoxazolines et leur utilisation en tant que pesticide
WO2010070068A2 (fr) 2008-12-19 2010-06-24 Novartis Ag Composés organiques
WO2011075591A1 (fr) 2009-12-17 2011-06-23 Merial Limited Dihydroazoles antiparasitaires et compositions les incluant
WO2011124998A1 (fr) 2010-04-08 2011-10-13 Pfizer Inc. Dérivés de 3,5-diphényl-isoxazoline substitués comme insecticides et acaricides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CASTRO-HERMIDA JOSÉ ANTONIO ET AL: "Current Challenges for Fasciolicide Treatment in Ruminant Livestock", TRENDS IN PARASITOLOGY, ELSEVIER CURRENT TRENDS, GB, vol. 37, no. 5, 15 January 2021 (2021-01-15), pages 430 - 444, XP086536721, ISSN: 1471-4922, [retrieved on 20210115], DOI: 10.1016/J.PT.2020.12.003 *
EDWARDS JBROWN MPEAK EBARTHOLOMEW BNASH RJHOFFMANN KF: "The Diterpenoid 7-Keto-Sempervirol, Derived from Lycium chinense, Displays Anthelmintic Activity against both Schistosoma mansoni and Fasciola hepatica", PLOS NEGLECTED TROPICAL DISEASES, vol. 9, no. 3, 15 March 2015 (2015-03-15), pages e0003604
GENNARO: "Remington: The Science and Practice of Pharmacy", 2000

Similar Documents

Publication Publication Date Title
US11712416B2 (en) Solid oral pharmaceutical compositions for isoxazoline compounds
US11896594B2 (en) Palatable antiparasitic formulations
RU2673723C1 (ru) Применение содержащих изоксазолин соединений в качестве противопаразитарных средств
CN113134008B (zh) 宠物用伊维菌素吡喹酮咀嚼片及其制备方法
US20150238446A1 (en) New treatment of fish with a nanosus pens ion of lufenuron or hexaflumuron
WO2024047241A1 (fr) Traitement de la fasciolose
JPH06211792A (ja) 寄生生物の全身的駆除
JP2003514834A (ja) 寄生虫を防除するためのｎ−フェニル−ｎ’−ベンゾイル尿素誘導体とネクチン化合物の組合せ
JP5981430B2 (ja) ハートワーム感染を治療するための組成物
AU2005336458B2 (en) Anthelmintic formulations
Taylor Use of anthelmintics in sheep
EA001623B1 (ru) Соединения из класса ацилмочевин, предназначенные для лечения кокцидиоидомикоза у теплокровных животных
US11903962B1 (en) Isoxazoline complexes and compositions thereof
RU2773154C1 (ru) Противопаразитарные составы с привлекательным вкусом
EP4076447B1 (fr) Lutte antiparasitaire chez les ruminants
Yadav et al. Medical management of Dipylidium caninum infected female cat: A case report
Herdiana et al. Drug Delivery System in Feline Yedi Herdiana1, 2, Gofarana Wilar2, 3, Ferry Ferdiansyah Sofian4, Annisa Dyah Pitaloka4, Yasinta Nurhijriah4, Rayhan Zarra Safira4, Annisa Siti Salsabila4, Maziyatunisa Z4
RU2772279C2 (ru) Твердые фармацевтические композиции для перорального введения на основе изоксазолиновых соединений
Miller The epidemiology and control of nematode parasites of ruminants in Texas
BORAY et al. Liver fluke–an essay–by Dr Joe Boray–comments/clarification
Jordan Rabbit Medicine
JPS5817444B2 (ja) 抗コクシジウム剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23764889

Country of ref document: EP

Kind code of ref document: A1